TrialLancet (London, England)2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
W Timothy Garvey et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
401 papers cite itlatest 60 shown
this paperpooled ittrialcites it